Life Sciences, RNA Editing
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.
Wave Life Sciences Stock Climbs on RNA Editing Progress
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T
Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities
Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Wave Life Sciences Shares Surge After RNA Editing Discovery
Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial,
Wave stock soars 66% on positive data for RNA editing treatment (update)
Wave Life Sciences (WVE) shares soared 66% after the company announced positive proof-of-mechanism data from a study of WVE-006 in the treatment of AATD. Read more here.
Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The
Merck KGaA Trims Health Care And Life Sciences Targets, Eyes M&A
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...
bovnews14h
180 Life Sciences Corp (ATNF) Stock Trading Recap
In recent trading, 180 Life Sciences Corp (ATNF) stock price has shown some volatility, fluctuating 372.26% over the last five trades and 225.13% over the past 30 trades. This represents a notable ...
Agilent Technologies in Chicopee scores life sciences tax incentive, commits to adding 10 jobs
CHICOPEE — Agilent Technologies in Chicopee received a $250,000 life sciences tax incentive and has committed to adding 10 ...
JD Supra1d
Healthcare & Life Sciences Private Equity Deal Tracker: GTCR to Acquire TRANZACT
GTCR has announced it will acquire TRANZACT. TRANZACT, founded in 1997 and based in Fort Lee, New Jersey, is a ...
WWLP Springfield on MSN2d
Tax incentives announced for life science companies in Mass.
Two western Massachusetts life science companies are among 19 across the state to receive tax incentive awards.
Inside Harlem’s unlikely ‘life-sciences’ boom
The $700 million Taystee Lab Building sits in the Manhattanville Factory District, but the laboratory goes beyond West Harlem ...
5 things to know about the Texas Research Quarter, the life sciences hub planned for Plano
The Texas Research Quarter is betting big on making Plano and North Texas a hub for life sciences. The development by ...
JD Supra6d
Life Sciences Snapshot – Q3 2024 – A Quarterly Report on Financing Trends
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2024 include: • Life sciences VC deal ...
Philadelphia life sciences leasing approaches ‘light at the end of the tunnel’
Stagnant for more than a year, Philadelphia’s life sciences leasing market is starting to percolate and industry insiders are ...
Lupus Foundation of America8h
UPDATE: Kezar Life Sciences Terminates Phase 2b Study of Zetomipzomib for Lupus Nephritis Treatment
Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...